Drug Discovery News and Research

RSS

The drug discovery process begins with recognizing a disease or clinical condition in which there is a lack of adequate medical treatment. Once a potential drug has been identified, pre-clinical research can begin. This process includes several stages; the first of which involves identifying and validating the prospective drug’s target through assay development, high throughput screening, hit identification and finally, lead optimization. Once the pre-clinical process is complete, the newly synthesized drug candidate is selected for future clinical development.

Ziath to participate in two key virtual biobanking symposia

Ziath announce their participation in two key virtual symposia for scientists involved in biobanking - the ISBER Virtual Symposium 2020 and the Europe Biobank Week 2020.

From Ziath Ltd 16 Oct 2020

Start-up receives NIH grant to accelerate development of contrast agent to detect liver fibrosis

Inlighta Biosciences, LLC, a start-up company led by Jenny Yang, Regents' Professor of Chemistry at Georgia State University, has been awarded a National Institute of Health grant to accelerate development of a magnetic resonance imaging contrast agent to detect liver fibrosis, formation of scar tissue in the liver caused by alcoholic and non-alcoholic fatty liver disease.

15 Oct 2020

Dotmatics introduces a self-service, scientific visualization and analytics application for small molecule discovery

Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has expanded its product portfolio to include Blueprint, a self-service, scientific visualization and analytics application for small molecule discovery.

From Dotmatics 15 Oct 2020

Ziath Announces Participation in Key Virtual Symposia

Ziath Announces Their Participation in Key Virtual Symposia

From Ziath Ltd 15 Oct 2020

New machine learning concepts can help develop novel drugs

Tandem mass spectrometry is a powerful analytical tool used to characterize complex mixtures in drug discovery and other fields.

14 Oct 2020

Axol Bioscience introduces multi-electrode array screening services for human iPSC-derived cells

Axol Bioscience today announced the expansion of its services, with the introduction of array screening for human induced pluripotent stem cells.

From Axol Bioscience Ltd 13 Oct 2020

In vitro BA-LRA can help detect small molecule drugs for drug-induced liver injury

BioIVT, a leading provider of research models and services for drug and diagnostic development, today announced the publication of research describing the use of HEPATOPAC® cultures with a targeted in vitro assay to identify small molecule drugs with high potential for drug-induced liver injury (DILI).

13 Oct 2020

Exciting findings on CD8 T cell response in recovered COVID patients

An international team of scientists has identified novel T cell-recognized epitopes spanning different proteins of severe acute respiratory syndrome coronavirus 2 in COVID-19 recovered patients. The scientists have also revealed phenotypical characteristics of the T cell population.

11 Oct 2020

Technological breakthrough may increase COVID-19 testing, reduce wait time and costs

The U.S. Food and Drug Administration has granted emergency use authorization for scientists at UCLA Health to begin using a new method of COVID-19 detection using sequencing technology called SwabSeq.

8 Oct 2020

Researchers use silk nanofibers to enhance 3D cell printing

How do you test, in early-stage research, whether a potential pharmaceutical effectively targets a human tumor, organ, or some other part of the body? How do you grow a new hand or some other body part?

8 Oct 2020

Comet supercomputer performs complex calculations on receptor sequence data from human T cells

While researchers around the world race to develop an effective and safe COVID-19 vaccine, a team from the San Diego Supercomputer Center (SDSC) at UC San Diego contributed to a study led by Vanderbilt Vaccine Center of Vanderbilt University Medical Center (VUMC) on T cell receptors, which play a vital role in alerting the adaptive immune system to mount an attack on invading foreign pathogens including the Coronavirus SARS-CoV-2.

8 Oct 2020

UC Davis School of Medicine and UTHealth receive NIH grant for dementia research

A team of brain scientists from UC Davis School of Medicine and The University of Texas Health Science Center at Houston has been awarded a six-year grant expected to total $53.6 million from the National Institutes of Health.

7 Oct 2020

Production of six monoclonal antibodies against SARS-CoV-2 spike protein

Youjia Guo et al. in a recent bioRxiv preprint paper demonstrate the robust performance of mouse anti-SARS-CoV-2 spike monoclonal antibodies in immunoassays, including western blotting, ELISA, immunofluorescence, and immunoprecipitation and also neutralizing activity in vitro against SARS-CoV-2 infection.

5 Oct 2020

Newly developed fusion protein could improve COVID-19 research

Researchers at the Paul Scherrer Institute in Switzerland have developed a high-quality recombinant virus protein that could be applied in the development of vaccines against the 2019 novel coronavirus (2019-nCoV) and in the detection of novel viruses or antibodies.

30 Sep 2020

Researchers identify a new method to produce miniaturized antibodies

Researchers at the University of Bath in the UK and biopharma company UCB have found a way to produce miniaturized antibodies, opening the way for a potential new class of treatments for diseases.

30 Sep 2020

Phase 1 trial of new class of drugs shows promise in range of advanced cancers

A new precision drug which stops cancer from repairing its DNA has shown promise in an early-stage clinical trial - highlighting the potential of a new class of drugs known as ATR inhibitors.

29 Sep 2020

A special issue on the emerging COVID-19 infection

Acta Pharmaceutica Sinica B publishes special issue on 'Research on Emerging COVID-19 (Target, Mechanism, and Therapeutics)' edited by Hai-Bin Luo, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, China; Shilin Chen, Institute of Chinese Materia Medica, Beijing, China and Peiqing Liu, School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou, China.

29 Sep 2020

Blocking nuclear pore complex formation can help selectively kill cancer cells

Scientists at Sanford Burnham Prebys Medical Discovery Institute have shown that blocking the construction of nuclear pores complexes--large channels that control the flow of materials in and out of the cell nucleus--shrank aggressive tumors in mice while leaving healthy cells unharmed.

28 Sep 2020

AXT add Vieworks bio-imaging solutions to their preclinical imaging portfolio

AXT is excited to add the Vieworks range of bio-imaging systems to their preclinical imaging product portfolio. Their in-vivo imaging systems provide outstanding performance in bioluminescent and fluorescent imaging and represents excellent value.

From AXT Pty Ltd 26 Sep 2020